A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia
Status:
Withdrawn
Trial end date:
2016-11-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability and potential efficacy of
IDH305 with standard treatments for newly diagnosed IDH1R132 mutant acute myeloid leukemia
(AML).